Zheng Quan Shi Bao Wang·2025-12-22 13:35Core Insights - The launch of Entacapone/Carbidopa/Levodopa tablets (brand name: Shenkang) by Qilu Pharmaceutical Group marks a significant advancement in the treatment of Parkinson's disease, particularly for patients experiencing motor fluctuations not controlled by standard therapies [1][2] Group 1: Product Overview - Shenkang is indicated for adult patients with Parkinson's disease who experience motor fluctuations despite treatment with Levodopa and DDC inhibitors [1] - The drug combines three active ingredients—Levodopa, Carbidopa, and Entacapone—into a single formulation, simplifying the treatment regimen and potentially improving patient adherence [1] - The Chinese Parkinson's Disease Treatment Guidelines recommend this combination therapy as the first-line treatment for patients with motor fluctuations [1] Group 2: Market Context - Parkinson's disease is the second most common neurodegenerative disorder in China, with a prevalence rate of approximately 1.7% among individuals aged 65 and older [1] - Qilu Pharmaceutical is a major player in the Chinese pharmaceutical industry, with a diverse product portfolio covering various therapeutic areas including oncology, infectious diseases, and central nervous system disorders [2] Group 3: Distribution and Management - Alibaba Health serves as the launch platform for Shenkang, providing a pathway for rapid access to target patients and enhancing disease management through professional medical education and pharmacy services [2] - The company emphasizes a comprehensive management approach for Parkinson's disease, utilizing digital tools for online follow-ups, medication reminders, and symptom tracking to improve treatment continuity and patient quality of life [2]